Haleon PLC Sponsored ADR $HLN Shares Purchased by WCM Investment Management LLC

WCM Investment Management LLC raised its position in shares of Haleon PLC Sponsored ADR (NYSE:HLN) by 70.3% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,725,059 shares of the company’s stock after purchasing an additional 711,817 shares during the quarter. WCM Investment Management LLC’s holdings in Haleon were worth $17,251,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the company. Parkside Financial Bank & Trust lifted its holdings in shares of Haleon by 101.3% in the fourth quarter. Parkside Financial Bank & Trust now owns 2,847 shares of the company’s stock valued at $29,000 after buying an additional 1,433 shares during the period. Annis Gardner Whiting Capital Advisors LLC grew its holdings in Haleon by 402.0% during the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares during the period. Geneos Wealth Management Inc. grew its holdings in Haleon by 33.0% during the first quarter. Geneos Wealth Management Inc. now owns 4,846 shares of the company’s stock worth $50,000 after acquiring an additional 1,203 shares during the period. Caitong International Asset Management Co. Ltd raised its position in Haleon by 428.1% in the third quarter. Caitong International Asset Management Co. Ltd now owns 6,321 shares of the company’s stock worth $57,000 after acquiring an additional 5,124 shares in the last quarter. Finally, Assetmark Inc. raised its position in Haleon by 26.6% in the fourth quarter. Assetmark Inc. now owns 5,962 shares of the company’s stock worth $60,000 after acquiring an additional 1,252 shares in the last quarter. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Stock Down 0.0%

Shares of Haleon stock opened at $10.10 on Monday. Haleon PLC Sponsored ADR has a 12-month low of $8.65 and a 12-month high of $11.28. The firm has a market capitalization of $44.46 billion, a PE ratio of 25.88, a price-to-earnings-growth ratio of 2.33 and a beta of 0.13. The company has a quick ratio of 0.71, a current ratio of 0.92 and a debt-to-equity ratio of 0.47. The stock’s fifty day moving average is $9.27 and its 200-day moving average is $9.86.

Analyst Upgrades and Downgrades

HLN has been the subject of several research reports. Rothschild & Co Redburn lowered shares of Haleon from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, June 16th. Deutsche Bank Aktiengesellschaft reiterated a “sell” rating on shares of Haleon in a report on Thursday, April 30th. Wall Street Zen raised shares of Haleon from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Haleon currently has a consensus rating of “Moderate Buy”.

About Haleon

Haleon plc (NYSE:HLN) is a global consumer healthcare company formed through the separation of a large pharmaceutical group’s consumer health business in 2022. Headquartered in the United Kingdom, Haleon develops, manufactures and markets a broad portfolio of over‑the‑counter medicines, oral health products, vitamins, minerals and supplements, and other consumer health goods designed for daily self‑care and symptom relief.

The company’s product mix spans categories such as oral care (toothpastes and sensitivity treatments), pain relief and analgesics, respiratory remedies, digestive health products, topical treatments and nutritional supplements.